BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22837180)

  • 1. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
    Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
    Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
    Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
    Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
    Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
    Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
    Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
    Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
    Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma.
    Courts C; Montesinos-Rongen M; Brunn A; Bug S; Siemer D; Hans V; Blümcke I; Klapper W; Schaller C; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2008 Jul; 67(7):720-7. PubMed ID: 18596541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
    Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
    Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
    Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
    Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of primary central nervous system lymphoma.
    Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
    Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
    Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
    Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma.
    Schwindt H; Vater I; Kreuz M; Montesinos-Rongen M; Brunn A; Richter J; Gesk S; Ammerpohl O; Wiestler OD; Hasenclever D; Deckert M; Siebert R
    Leukemia; 2009 Oct; 23(10):1875-84. PubMed ID: 19494841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of primary central nervous system lymphoma.
    Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
    Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1.
    Parker H; An Q; Barber K; Case M; Davies T; Konn Z; Stewart A; Wright S; Griffiths M; Ross FM; Moorman AV; Hall AG; Irving JA; Harrison CJ; Strefford JC
    Genes Chromosomes Cancer; 2008 Dec; 47(12):1118-25. PubMed ID: 18767146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
    Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
    Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.